Albrecht Graeve - UCB SA Non-Executive Independent Director

UCBJY Stock  USD 58.22  1.22  2.14%   

Director

Mr. Albrecht De Graeve has served as Independent NonExecutive Director of UCB S.A. since April 29, 2010. He is Chairman of the Company Audit Committee, Member of the Audit Committee as of April 29, 2010. He was Chairman of Bekaert NV, Telenet Group Holding NV and Sibelco NV. He became Chief Executive Officer of the Bekaert Group in May 2006. From 2002 until May 2006 he was Chief Financial and Administration Officer and General Secretary of the Group. He started his career in 1980 with Arthur Andersen Co and joined Alcatel Bell in 1982. In 1991 he became General Manager Shanghai Bell Telephone Equipment Mfg. Cy in Shanghai. In 1994 he was appointed Vice President, Director Operations, Alcatel Trade International and later Director International Affairs, Alcatel Alsthom in Paris. In 1996 he became Managing Director of the Flemish Public Radio TV Broadcaster . He holds a Master in Law from the University of Ghent, studied Financial Management at IPO and became Master in Tax Management at VLEKHO since 2010.
Age 63
Tenure 14 years
Phone32 2 559 99 99
Webhttps://www.ucb.com
De Graeve was appointed Member of the International Business Leaders' Advisory Council for the Mayor of Shanghai, President of the FlandersChina Chamber of Commerce, Member of the Advisory Board of the Conference Board China Center for Economics and Business in Beijing and Member of the Board of the Concours Reine Elisabeth. He received a Masters degree in Law from Universiteit Gent in 1980. He also holds a Masters degree in Tax from Vlaamse Economische Hogeschool, and a Masters degree in Financial Management from Instituut voor Postuniversitair Onderwijs, Antwerp .

UCB SA Management Efficiency

The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.97 B in total debt with debt to equity ratio (D/E) of 0.34, which is about average as compared to similar companies. UCB SA ADR has a current ratio of 1.1, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist UCB SA until it has trouble settling it off, either with new capital or with free cash flow. So, UCB SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like UCB SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for UCB to invest in growth at high rates of return. When we think about UCB SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Terrence KearneyVertex Pharmaceuticals
63
David AltshulerVertex Pharmaceuticals
53
Anne KvernelandNovo Nordisk AS
64
David GreenwayVertex Pharmaceuticals
34
Joshua LewisPearson PLC ADR
53
Michael BrownRegeneron Pharmaceuticals
77
Bonnie BasslerRegeneron Pharmaceuticals
55
Marc TessierLavigneRegeneron Pharmaceuticals
58
Harish ManwaniPearson PLC ADR
64
Eivind KoldingNovo Nordisk AS
55
Lincoln WallenPearson PLC ADR
60
Graeme PitkethlyPearson PLC ADR
54
Laurence DebrouxNovo Nordisk AS
51
Stig StroebaekNovo Nordisk AS
55
Joseph RamelliModerna
47
Sangeeta BhatiaVertex Pharmaceuticals
49
Arthur RyanRegeneron Pharmaceuticals
75
Elaine UllianVertex Pharmaceuticals
69
Linda LorimerPearson PLC ADR
68
Michael LyntonPearson PLC ADR
61
Coram WilliamsPearson PLC ADR
44
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people. UCB SA ADR [UCBJY] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.

Management Performance

UCB SA ADR Leadership Team

Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Caroline Vancoillie, Chief Functions
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Sandrine CFA, Ex CFO
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
William Silbey, Exec Counsel
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Pr LowFriedrich, Chief VP
Kirsten LundJurgensen, Ex Solutions
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

UCB Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards UCB SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, UCB SA's short interest history, or implied volatility extrapolated from UCB SA options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for UCB Pink Sheet analysis

When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Please note, there is a significant difference between UCB SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if UCB SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UCB SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.